{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-113410","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2024-10-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.928391+00:00","generated_at":"2026-05-30T18:15:21.177372+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PepGen reports favorable safety profile for PGN-EDO51 in Phase 2 DMD trial at WMS Congress","bullets":["CONNECT1-EDO51 safety data as of Oct 3: no serious adverse events; all treatment-related AEs mild and resolved.","One hypomagnesemia case resolved with oral supplementation; no discontinuations, dose interruptions or reductions.","Presenting short oral and five posters on PGN-EDO51 (DMD) and PGN-EDODM1 (DM1) at WMS Congress in Prague Oct 8-12.","Nonclinical data for both programs and FREEDOM-DM1 trial design also featured in poster sessions."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-113410","json":"https://secwatch.observer/filing/0000950170-24-113410.json","markdown":"https://secwatch.observer/filing/0000950170-24-113410.md","text":"https://secwatch.observer/filing/0000950170-24-113410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024113410/0000950170-24-113410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024113410/pepg-20241008.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T18:15:21.177372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}